Chlorine dioxide as COVID-19 prevention and treatment
01
What institutions accepted
Chlorine dioxide solution was treated as a medically usable alternative for preventing or treating COVID-19, making statutory pharmacy access, public-health supply, official information campaigns and judicially enforceable patient access appropriate.
02
What the evidence supports now
Chlorine dioxide is a reactive oxidizing chemical used for disinfection and industrial purposes. Activity against microbes outside the body does not establish a safe or effective systemic treatment. A 2020 systematic review found no human studies supporting inhaled, oral or parenteral use against COVID-19, and a later randomized trial of the much narrower practice of dilute chlorine-dioxide mouth rinsing found no reduction in salivary SARS-CoV-2 viral titer versus water. PAHO advised against oral or parenteral use because efficacy was unproved and serious adverse effects were possible; poison-centre data document acute gastrointestinal, electrolyte and other harms after exposure.
03
Evidence for the overall belief
Open sources, locators and notes
- DocumentsHistorical beliefLey Nº 1351 — Solución de Dióxido de Cloro como prevención y tratamiento ante la pandemia del COVID-19Unidad de Análisis de Políticas Sociales y Económicas (UDAPE), Estado Plurinacional de Bolivia
Where in the source: Arts. 1, 4(b), 5–10; pp. 1–3
The statute expressly frames chlorine dioxide as prevention and treatment, permits pharmacy sale without a prescription, requires public-health supply and assigns communication, acquisition and free-distribution duties.
- SupportsPresent correctionChlorine dioxide and chlorine derivatives for the prevention or treatment of COVID-19 — a systematic reviewRevista Peruana de Medicina Experimental y Salud Pública / SciELO
Where in the source: Abstract and Results; pp. 605–610
PRISMA-based review found no published or preprint human study of inhaled, oral or parenteral chlorine dioxide or derivatives for COVID-19 or other coronavirus infections at the search date; one registered observational study had no results.
- SupportsPresent correctionPAHO Does Not Recommend Taking Products that Contain Chlorine Dioxide, Sodium Chlorite, Sodium Hypochlorite, or Derivatives, 16 July 2020Pan American Health Organization
Where in the source: Key messages, p. 1; Toxicity, pp. 2–3
PAHO advises against oral or parenteral use for suspected or diagnosed COVID-19 or any other case, citing no evidence of effectiveness and the possibility of serious adverse effects from ingestion or inhalation.
- SupportsPresent correctionA multicenter, randomized, open-label, placebo-controlled clinical trial of the effect of cetylpyridinium chloride (CPC) mouthwash and on-demand aqueous chlorine dioxide mouthwash on SARS-CoV-2 viral titer in patients with mild COVID-19Journal of Evidence-Based Dental Practice / PubMed
Where in the source: Abstract, Methods and Results
In a randomized trial, 0.01% aqueous chlorine-dioxide mouthwash did not reduce salivary SARS-CoV-2 viral titer versus purified water at 10, 30 or 60 minutes. This narrow mouth-rinse result supplies no evidence for internal administration.
- SupportsPresent correctionHarmful effects of chlorine dioxide exposureClinical Toxicology / PubMed Central
Where in the source: pp. 448–449 and Table 1
Analysis of 53 U.S. poison-centre exposures found ingestion was the most common route; vomiting, nausea, abdominal pain and diarrhea were frequent, 13 patients were hospitalized, and two required critical care.
- DocumentsImpactLey Nº 1351 — Solución de Dióxido de Cloro como prevención y tratamiento ante la pandemia del COVID-19Unidad de Análisis de Políticas Sociales y Económicas (UDAPE), Estado Plurinacional de Bolivia
Where in the source: Arts. 4–11; pp. 1–3
Documents the scale of the legal framework: non-prescription sale, public-sector supply, information, acquisition, free distribution and financing responsibilities.
04
Impact
Bolivia's national institutions took conflicting positions. AGEMED and the Ministry of Health said chlorine dioxide was not an authorized medicine, lacked evidence against COVID-19 and could cause serious harm. The legislature nevertheless promulgated Law 1351, which authorized non-prescription sale and assigned public bodies supply, acquisition, free-distribution and information duties. In 2022 the Constitutional Tribunal upheld relief allowing outside medical personnel to assess and provide the requested treatment in one hospital case; in 2023 a different chamber denied relief in another case on proof and causation grounds. Neither judgment independently validated efficacy.
Context
The Ministry of Health and AGEMED were dissenting public-health institutions in this episode, rather than carriers of the disputed medical proposition. Law 1351 nevertheless assigned implementation duties to the ministry and to departmental and municipal governments.
Bolivia ended its national COVID-19 health emergency on 31 July 2023. That administrative endpoint did not itself repeal Law 1351. No formal legislative repeal was located in the reviewed official record, and a Bolivian legal database still labelled the statute in force at the review date.
AGEMED and the Health Ministry rejected the claimed treatment basis before the law was promulgated
Law 1351 made chlorine dioxide a legally recognized COVID-19 prevention and alternative-treatment option
Constitutional rulings produced different case-specific access outcomes without resolving scientific efficacy
Historical totals and effects are presented as contextual evidence, not as universal causal claims.
Institutional episode 01
Bolivia
Latin America
Bolivia's medicines regulator and Health Ministry warned in June and July 2020 that chlorine dioxide was not an authorized medicine, had no scientific basis as a COVID-19 treatment and posed serious risks. The Asamblea Legislativa Plurinacional nevertheless made the proposition operational through Law 1351 in October 2020. The law created access and public-supply duties that a 2022 Constitutional Tribunal judgment applied in a hospital case by requiring access for outside medical personnel. A 2023 judgment denied a different claim because the alleged refusal and causal harm had not been proved, illustrating that the 2022 outcome was case-specific rather than a general scientific endorsement. The national health emergency ended in July 2023, but no formal repeal of Law 1351 was identified in the reviewed official material.
Institutions involved
- Asamblea Legislativa Plurinacional
- Tribunal Constitucional Plurinacional
Institutional context
Law 1351 was passed by the legislature and promulgated by its acting president on 14 October 2020 after AGEMED and the Health Ministry had already rejected the medical premise. Articles 4 through 10 allowed pharmacy sale without prescription, required departmental and municipal governments to guarantee supply in the public-health subsector, permitted consented use as prevention or alternative treatment, and assigned information, acquisition and free-distribution duties. In SCP 0052/2022-S2, the Constitutional Tribunal reasoned from Articles 5 and 6 when it upheld relief requiring a hospital to admit outside specialized medical personnel to assess and provide the requested treatment; it did not order the hospital's own clinicians to administer chlorine dioxide or conduct a scientific efficacy review. SCP 0052/2023-S4 later denied relief in a different hospital case because the claimant had not proved a timely refusal or that the hospital caused the patient's deterioration and death. The second judgment did not invalidate Law 1351 or decide that chlorine dioxide was effective.
Why this persisted
Administrative adoptionThe legislature converted an unsupported therapeutic proposition into a national statutory framework for sale, supply, distribution and public communication; constitutional litigation then made the access provisions enforceable in one hospital case.
How correction happened
Partially corrected2020–2023
Action: Health agencies rejected the medical premise, a later constitutional judgment denied a separate access claim on proof grounds, and the national COVID-19 emergency ended; the legislature did not document a repeal or retraction.
Correction was institutionally split rather than a clean reversal. AGEMED and the Health Ministry rejected the proposition from the outset, and the 2023 judgment did not repeat the 2022 access result in a factually different case. Ending the emergency closed the operational period used for this episode, but it did not expressly repeal the statute. The reviewed record therefore supports only a partial correction, not a legislative repudiation of Law 1351.
Consequences
- Legal recognition of chlorine dioxide as an alternative COVID-19 prevention and treatment option
- Statutory duties for public-sector supply, acquisition, free distribution and information campaigns
- Pharmacy sale without a prescription under the statutory framework
- Conflict between the statute and the evidence-based position of the national medicines regulator and Health Ministry
- Constitutional litigation that granted access in one hospital case and denied relief on proof grounds in another
Evidence for this episode
14 evidence linksOpen sources, locators and notes
- DocumentsInstitutional carrierLey Nº 1351 — Solución de Dióxido de Cloro como prevención y tratamiento ante la pandemia del COVID-19Unidad de Análisis de Políticas Sociales y Económicas (UDAPE), Estado Plurinacional de Bolivia
Where in the source: Heading and promulgation clause, pp. 1 and 4
Identifies the Asamblea Legislativa Plurinacional as the enacting institution and its acting president as the official who promulgated the law on 14 October 2020.
- DocumentsMechanismLey Nº 1351 — Solución de Dióxido de Cloro como prevención y tratamiento ante la pandemia del COVID-19Unidad de Análisis de Políticas Sociales y Económicas (UDAPE), Estado Plurinacional de Bolivia
Where in the source: Arts. 3–11; pp. 1–3
- ContextualizesContextCircular MS/AGEMED/CR/60/2020 — comunicado sobre dióxido de cloro y clorito de sodioAgencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED), Ministry of Health
Where in the source: Circular dated 26 June 2020, p. 1
AGEMED stated before promulgation that the marketed products were not authorized medicines, had no registration supporting safety, quality or efficacy, lacked evidence against COVID-19 and posed serious health risks.
- ContextualizesContextCircular MS/AGEMED/CR/67/2020 — Estudios Clínicos con Dióxido de CloroAgencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED), Ministry of Health
Where in the source: Circular dated 8 July 2020, p. 1
AGEMED again stated that no scientific evidence supported treatment and directed proponents to submit properly approved clinical-study protocols if they wished to generate evidence.
- ContextualizesContextComunicado del Ministerio de Salud sobre el denominado Comité Boliviano de Solución de Dióxido de CloroMinistry of Health, Bolivia
Where in the source: Communiqué dated 20 July 2020
The Health Ministry denied institutional recognition to the self-described committee promoting chlorine dioxide and said its proposed protocols lacked a scientific basis and put lives at risk.
- DocumentsMechanismSentencia Constitucional Plurinacional 0052/2022-S2Tribunal Constitucional Plurinacional de Bolivia
Where in the source: SCP 0052/2022-S2, judgment pp. 19–21
The Tribunal relied on Law 1351, especially Articles 5 and 6, and confirmed relief requiring the hospital to allow outside specialized medical personnel to assess and provide the requested treatment.
- DocumentsConsequencesSentencia Constitucional Plurinacional 0052/2022-S2Tribunal Constitucional Plurinacional de Bolivia
Where in the source: SCP 0052/2022-S2, judgment pp. 20–21
The holding made statutory access effective in the particular hospital case. It did not require the hospital's own doctors to administer the product and did not independently determine clinical efficacy.
- DocumentsInstitutional correctionResolución Ministerial Nº 0461 — Se levanta la emergencia sanitaria nacional contra la COVID-19Ministry of Health and Sports, Bolivia
Where in the source: Resolución Ministerial 0461, Art. 1
Ends the national COVID-19 health emergency from 31 July 2023. It supports the operational endpoint used here, not a claim that Law 1351 was expressly repealed.
- ContextualizesContextPAHO Does Not Recommend Taking Products that Contain Chlorine Dioxide, Sodium Chlorite, Sodium Hypochlorite, or Derivatives, 16 July 2020Pan American Health Organization
Where in the source: Key messages, p. 1
- ContextualizesContextChlorine dioxide and chlorine derivatives for the prevention or treatment of COVID-19 — a systematic reviewRevista Peruana de Medicina Experimental y Salud Pública / SciELO
Where in the source: Search completed 10 August 2020; Results, pp. 607–608
Shows the evidentiary state contemporaneous with the statute: the systematic search located no human outcome study supporting the preventive or therapeutic proposition.
- SupportsConsequencesHarmful effects of chlorine dioxide exposureClinical Toxicology / PubMed Central
Where in the source: Table 1 and discussion, pp. 448–449
Provides empirical toxicity context for the exposure risk created when institutions normalize chlorine-dioxide use; it does not estimate how many Bolivians used the product under Law 1351.
- ContextualizesContextA multicenter, randomized, open-label, placebo-controlled clinical trial of the effect of cetylpyridinium chloride (CPC) mouthwash and on-demand aqueous chlorine dioxide mouthwash on SARS-CoV-2 viral titer in patients with mild COVID-19Journal of Evidence-Based Dental Practice / PubMed
Where in the source: Abstract and trial registration jRCTs031230566
Later randomized evidence on a dilute mouth rinse found no viral-titer benefit over water and cannot be generalized into support for the oral or parenteral administration contemplated by pandemic cure claims.
- DocumentsInstitutional correctionSentencia Constitucional Plurinacional 0052/2023-S4Tribunal Constitucional Plurinacional de Bolivia, reproduced by Jurisprudencia Constitucional
Where in the source: Sections III.4 and Por Tanto
In a separate case, the Tribunal confirmed denial of relief because the claimant did not prove a timely refusal or causation. The ruling limited the requested remedy on the record before it; it did not invalidate the statute or scientifically validate chlorine dioxide.
- ContextualizesInstitutional correctionLey 1351 — texto y estado de vigenciaInfoleyes Bolivia
Where in the source: Status header “Vigente”; reviewed 27 September 2026
The legal database continued to label Law 1351 in force at the review date. This supports caution against treating the end of the health emergency as an express legislative repeal.
Source registryEach source is registered once and can carry several precise evidence relationships.12 sources
- 01Ley Nº 1351 — Solución de Dióxido de Cloro como prevención y tratamiento ante la pandemia del COVID-19Unidad de Análisis de Políticas Sociales y Económicas (UDAPE), Estado Plurinacional de Bolivia4 evidence links
- 02Circular MS/AGEMED/CR/60/2020 — comunicado sobre dióxido de cloro y clorito de sodioAgencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED), Ministry of Health1 evidence link
- 03Circular MS/AGEMED/CR/67/2020 — Estudios Clínicos con Dióxido de CloroAgencia Estatal de Medicamentos y Tecnologías en Salud (AGEMED), Ministry of Health1 evidence link
- 041 evidence link
- 05Sentencia Constitucional Plurinacional 0052/2022-S2Tribunal Constitucional Plurinacional de Bolivia2 evidence links
- 06Resolución Ministerial Nº 0461 — Se levanta la emergencia sanitaria nacional contra la COVID-19Ministry of Health and Sports, Bolivia1 evidence link
- 072 evidence links
- 08Chlorine dioxide and chlorine derivatives for the prevention or treatment of COVID-19 — a systematic reviewRevista Peruana de Medicina Experimental y Salud Pública / SciELO2 evidence links
- 09Harmful effects of chlorine dioxide exposureClinical Toxicology / PubMed Central2 evidence links
- 102 evidence links
- 11Sentencia Constitucional Plurinacional 0052/2023-S4Tribunal Constitucional Plurinacional de Bolivia, reproduced by Jurisprudencia Constitucional1 evidence link
- 121 evidence link